Roth Capital analyst Kyle Bauser lowered the firm’s price target on Sanuwave Health (SNWV) to $47 from $53 and keeps a Buy rating on the shares. Despite an FY26 revenue outlook of $51M-55M that missed consensus of $58.0M, the firm views the outlook as “favorable given the disruption from skin sub reimbursement changes,” the analyst tells investors in a post-earnings note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNWV:
- Midday Fly By: Carnival cuts forecast on fuel cost, Novartis to buy Excellergy
- Sanuwave Health reports Q4 adjusted EBITDA $4.77M vs $3.66M last year
- Sanuwave Health sees Q1 revenue $9.6M-$10.3M
- Sanuwave Health sees FY26 revenue $51M-$55M
- SNWV Earnings Report this Week: Is It a Buy, Ahead of Earnings?